AC Immune (ACIU) Common Equity (2014 - 2025)

AC Immune (ACIU) has 12 years of Common Equity data on file, last reported at $56.2 million in Q4 2025.

• Quarterly Common Equity fell 56.18% year-over-year to $56.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $56.2 million (down 56.18% YoY) and the FY2025 annual result came in at $54.1 million, down 57.76% from the prior year.
• Common Equity eased to $56.2 million in Q4 2025 per ACIU's latest filing, from $90.3 million in the prior quarter.
• Across five years, Common Equity topped out at $251.6 million in Q4 2021 and bottomed at $56.2 million in Q4 2025.
• The 5-year median for Common Equity is $155.0 million (2023), against an average of $152.3 million.
• The widest annual swing landed in 2021, when Common Equity grew 5.55%; it then plunged 56.18% in 2025.
• Tracing ACIU's Common Equity over 5 years: stood at $251.6 million in 2021, then sank by 30.27% to $175.4 million in 2022, then climbed by 3.24% to $181.1 million in 2023, then slipped by 29.23% to $128.2 million in 2024, then tumbled by 56.18% to $56.2 million in 2025.
• Per Business Quant, the three latest ACIU Common Equity figures stand at $56.2 million (Q4 2025), $90.3 million (Q2 2025), and $128.2 million (Q4 2024).

Peer Comparison